naled
runge agrichems pty ltd - naled - unknown - naled organophosphorus active 0.0 - active constituent
lane dibrom ulv insecticide
bayer cropscience pty ltd - naled - insecticide - cotton | insect breeding area | pasture | sudan grass | sugar cane | high intensity usage | inter-row spraying | ratoon sugar ca - locust | mosquito | sand fly (biting midge) | adult mosquitoes
lane dibrom ec insecticide
bayer cropscience pty ltd - naled - insecticide - broom millet | cabbage | cauliflower | cucurbit | flower | fruit crop or tree | green bean | green or garden pea | hops | insect - aphid | armyworm | cabbage white butterfly | cockroach | common armyworm - mythimna convecta | corn earworm | cutworm - agrotis spp. | fly | green vegetable bug | leafhopper | mosquito | native budworm or bollworm | pumpkin beetle | red spider mite | southern or barley armyworm | thrip | vegetable or green looper | adult mosquitoes | barley armyworm | barley grub | cotton bollworm | heliothis | large cockroach | leucania convecta | looper caterpillar | native bollworm | plusia chalcites | small cockroach | southern armyworm | spodoptera spp. | thrips spp. | tobacco budworm | tomato grub
depo-provera- medroxyprogesterone acetate injection, suspension
pharmacia & upjohn company llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - depo-provera ci is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of depo-provera ci is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of depo-provera ci is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to depo-provera ci (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)] . - undiagnosed vaginal bleeding [see warnings and precautions (5.10)] . depo-provera ci
depo-provera- medroxyprogesterone acetate injection, suspension
a-s medication solutions - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - depo-provera ci is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use depo-provera ci long-term [see warnings and precautions (5.1) ]. the use of depo-provera ci is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to depo-provera ci (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)] . - undiagnosed vaginal bleeding [see warnings a
medroxyprogesterone acetate injection, suspension, extended release
amphastar pharmaceuticals, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - medroxyprogesterone acetate is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate long-term [see warnings and precautions (5.1)] . the use of medroxyprogesterone acetate is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)]. - known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.6)]. - undiagnosed vaginal bleeding
depo-provera- medroxyprogesterone acetate injection, suspension
a-s medication solutions - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - depo-provera ci is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use depo-provera ci long-term [see warnings and precautions (5.1) ]. the use of depo-provera ci is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to depo-provera ci (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)] . - undiagnosed vaginal bleeding [see warnings a
medroxyprogesterone acetate injection, suspension, extended release
nucare pharmaceuticals,inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate long-term [see warnings and precautions (5.1)] . the use of medroxyprogesterone acetate is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)]. - known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients
medroxyprogesterone acetate injection, suspension, extended release
a-s medication solutions - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate long-term [see warnings and precautions (5.1)] . the use of medroxyprogesterone acetate is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)]. - known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.6)]. - undiagnosed vaginal bleeding
medroxyprogesterone acetate injection, suspension, extended release
amphastar pharmaceuticals, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate long-term [see warnings and precautions (5.1)] . the use of medroxyprogesterone acetate is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)]. - known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.6)]. - undiagnosed vaginal bleeding